Cancer Biology

At the intersection of immunology and metabolism is a burgeoning new field: immunometabolism. It’s an area where Vanderbilt has exceptional strengths, said Jeffrey Rathmell, Ph.D., Cornelius Vanderbilt Professor of Immunobiology. Read More

Vanderbilt researchers have discovered a link between Helicobacter pylori infection, inflammation and gastric cancer that could suggest new anti-cancer therapies. Read More

Researchers at Vanderbilt University School of Medicine have uncovered a link between epidermal growth factor receptor (EGFR) signaling and the inflammatory response to bacterial infection in the gastrointestinal tract. Read More

The discoveries that can change the course of human health forever often begin in the tiniest places: in molecules and cells, at the most fundamental intersection of physics, chemistry and biology. Understanding how these cellular and molecular processes work is the focus of basic biomedical research at Vanderbilt. Read More

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers. Read More

The sphere-forming frequency of neuroblastoma cells is a measure of their proliferative capacity and could help guide treatment strategies for neuroblastoma. Read More

Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers. Read More

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been selected to testify before members of Congress about the importance of cancer research, including early training programs for individuals interested in science. Read More

New findings identify isoketal-modified proteins as a previously unrecognized feature of pulmonary fibrosis and as a potential therapeutic target for this disease. Read More

Craig Thompson, M.D., president and CEO of Memorial Sloan Kettering Cancer Center, spoke about his lab’s research linking metabolism to stem cell maintenance during his recent Flexner Discovery Lecture. Read More

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods. Read More

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment. Read More

A genetic mutation that promotes cancer development blocks the normal sorting of a protein called “Argonaute 2.” Read More

Craig Thompson, M.D., president and CEO of Memorial Sloan Kettering Cancer Center, will deliver the next Flexner Discovery Lecture on May 5. Read More

The p73 gene is required for the generation of cilia – hair-like projections on cells – findings that could have implications for the study of lung diseases and sterility. Read More

Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy. Read More

Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients. Read More

A protein that suppresses a key cancer pathway in the colon may be a potential biomarker for colitis-associated tumors, researchers at Vanderbilt University Medical Center reported last month in the journal Gut. Read More

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients. Read More

Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer. Read More